CEO: Christian Itin

Advent Contact: Don Drakeman

BITEs: first-in-class bi-specific antibodies

Micromet's BiTE (bi-specific T cell engager) antibody technology platform led to the creation of a clinical pipeline focused on new treatments for cancer and other conditions. The lead product from the Micromet pipeline, BlincytoTM (Blinatumomab), was approved as a second-line treatment for relapsed or refractory acute lymphoblastic leukaemia.

Advent invested in 2001. Micromet listed on NASDAQ in 2006 (NASDAQ:MITI), and was acquired by Amgen for $1.16B in 2012.